167 related articles for article (PubMed ID: 1610857)
41. Induction immunotherapy in heart transplantation with T10B9.1A-31: a phase I study.
Waid TH; Thompson JS; McKeown JW; Brown SA; Sekela ME
J Heart Lung Transplant; 1997 Sep; 16(9):913-6. PubMed ID: 9322140
[TBL] [Abstract][Full Text] [Related]
42. [Humoral immunopathologic changes in the myocardium after clinical allotransplantation of the heart].
Beletskaia LV; Baranova FS; Khalimova ZA; Kurenkova LG; Kazakov EN; Kormer AI; Chestukhin VV; Za'idenov Va; Boikina TV; Selezneva EA
Arkh Patol; 1995; 57(6):3-7. PubMed ID: 8742178
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of plasma cyclic GMP assay as a screening test for detection of acute cardiac allograft rejection.
Stobierska-Dzierzek B; Surdacki A; Frasik W; Dziatkowiak A; Pietrucha A; Herman ZS; Piwowarska W
J Heart Lung Transplant; 1998 Oct; 17(10):969-71. PubMed ID: 9811403
[TBL] [Abstract][Full Text] [Related]
44. Treatment of cardiac allograft rejection with intravenous corticosteroids.
Miller LW
J Heart Transplant; 1990; 9(3 Pt 2):283-7. PubMed ID: 2355284
[TBL] [Abstract][Full Text] [Related]
45. "Quilty effect" in heart transplantation: is it related to acute rejection?
Pardo-Mindán FJ; Lozano MD
J Heart Lung Transplant; 1991; 10(6):937-41. PubMed ID: 1756159
[TBL] [Abstract][Full Text] [Related]
46. Ten-year follow-up of a prospective, randomized trial of BT563/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation.
Bonaros N; Dunkler D; Kocher A; Imhof M; Grimm M; Zuckermann A; Wolner E; Laufer G
J Heart Lung Transplant; 2006 Sep; 25(9):1154-63. PubMed ID: 16962480
[TBL] [Abstract][Full Text] [Related]
47. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy.
Cantarovich M; Latter DA; Loertscher R
Clin Transplant; 1997 Aug; 11(4):316-21. PubMed ID: 9267721
[TBL] [Abstract][Full Text] [Related]
48. Mortality and morbidity in pre-sensitized pediatric heart transplant recipients with a positive donor crossmatch utilizing peri-operative plasmapheresis and cytolytic therapy.
Holt DB; Lublin DM; Phelan DL; Boslaugh SE; Gandhi SK; Huddleston CB; Saffitz JE; Canter CE
J Heart Lung Transplant; 2007 Sep; 26(9):876-82. PubMed ID: 17845925
[TBL] [Abstract][Full Text] [Related]
49. Relationship of increased levels of circulating intercellular adhesion molecule 1 after heart transplantation to rejection: human leukocyte antigen mismatch and survival.
Ballantyne CM; Mainolfi EA; Young JB; Windsor NT; Cocanougher B; Lawrence EC; Pollack MS; Entman ML; Rothlein R
J Heart Lung Transplant; 1994; 13(4):597-603. PubMed ID: 7947875
[TBL] [Abstract][Full Text] [Related]
50. Graft arteriosclerosis-induced myocardial pathology in heart transplant recipients: predictive value of endomyocardial biopsy.
Winters GL; Schoen FJ
J Heart Lung Transplant; 1997 Oct; 16(10):985-93. PubMed ID: 9361240
[TBL] [Abstract][Full Text] [Related]
51. [The pivotal role of the pathologist in transplantation].
Rotman S; Fontana M; Seydoux C; Venetz JP; Aubert JD; Pascual M
Rev Med Suisse; 2008 Feb; 4(145):480-3. PubMed ID: 18376526
[TBL] [Abstract][Full Text] [Related]
52. Diagnostic validity of hepatocyte growth factor as marker for rejection in the follow-up of patients after heart transplantation.
Zwirska-Korczala K; Zakliczyński M; Berdowska A; Zembala M; Jochem J; Gajewska K
J Heart Lung Transplant; 2005 Apr; 24(4):411-5. PubMed ID: 15797741
[TBL] [Abstract][Full Text] [Related]
53. Surveillance for rejection by echocardiographically guided endomyocardial biopsy in the infant heart transplant recipient.
Canter CE; Appleton RS; Saffitz JE; Bologna S; Miller L; Pennington DG; Spray TL
Circulation; 1991 Nov; 84(5 Suppl):III310-5. PubMed ID: 1934425
[TBL] [Abstract][Full Text] [Related]
54. Cardiac allograft rejection.
Patel JK; Kittleson M; Kobashigawa JA
Surgeon; 2011 Jun; 9(3):160-7. PubMed ID: 21550522
[TBL] [Abstract][Full Text] [Related]
55. The Impella 2.5 L for percutaneous mechanical circulatory support in severe humoral allograft rejection.
Beyer AT; Hui PY; Hauesslein E
J Invasive Cardiol; 2010 Mar; 22(3):E37-9. PubMed ID: 20197587
[TBL] [Abstract][Full Text] [Related]
56. Role of endomyocardial biopsy in rejection surveillance after heart transplantation in neonates and children.
Zales VR; Crawford S; Backer CL; Pahl E; Webb CL; Lynch P; Mavroudis C; Benson DW
J Am Coll Cardiol; 1994 Mar; 23(3):766-71. PubMed ID: 8113563
[TBL] [Abstract][Full Text] [Related]
57. [Noninvasive diagnosis of acute cellular rejection of transplanted heart].
Sidorenko IV; Vaĭkhanskaia TG; Ostrovskiĭ IuP; Iudina OA; Rachok LV; Koliadko MG; Dubovik TA; Kurlianskaia EK; Ostrovskiĭ AIu
Kardiologiia; 2011; 51(8):59-65. PubMed ID: 21942961
[TBL] [Abstract][Full Text] [Related]
58. A summary of bortezomib use in transplantation across 29 centers.
Everly MJ
Clin Transpl; 2009; ():323-37. PubMed ID: 20524294
[TBL] [Abstract][Full Text] [Related]
59. Optimal timing for surveillance endomyocardial biopsies in heart transplant patients receiving antithymocyte globulin induction.
Cantarovich M; de Gruchy S; Forbes C; Marpole D; Elstein E; Magnan C; de Varennes B
Transplant Proc; 1999; 31(1-2):79. PubMed ID: 10083015
[No Abstract] [Full Text] [Related]
60. Current expectations in cardiac transplantation.
Baumgartner WA; Reitz BA; Bieber CP; Oyer PE; Shumway NE; Stinson EB
J Thorac Cardiovasc Surg; 1978 Apr; 75(4):525-30. PubMed ID: 347177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
